Histone deacetylases and mechanisms of regulation of gene expression.
暂无分享,去创建一个
Hong Ping Chen | Yu Tina Zhao | Ting C Zhao | Y. Zhao | T. Zhao | Hong Chen
[1] Charles Giardina,et al. HDAC3 overexpression and colon cancer cell proliferation and differentiation , 2008, Molecular carcinogenesis.
[2] J. Mariadason,et al. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy , 2007, Cancer biology & therapy.
[3] Andrew J. Wilson,et al. Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy , 2012, Journal of Ovarian Research.
[4] Stuart L Schreiber,et al. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[5] G. Natoli,et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages , 2012, Proceedings of the National Academy of Sciences.
[6] H. Moon,et al. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[7] I. Irminger-Finger,et al. HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b , 2013, PloS one.
[8] I. Christensen,et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas , 2009, Histopathology.
[9] J. Nam,et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. , 2008, Journal of gynecologic oncology.
[10] N. Rosen,et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. , 2007, Molecular cell.
[11] Zhi-xiang Shen,et al. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma , 2013, Journal of Hematology & Oncology.
[12] T. Shiozawa,et al. Type‐specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E‐cadherin , 2010, International journal of cancer.
[13] E. Olson,et al. Histone deacetylases 1 and 2 control the progression of neural precursors to neurons during brain development , 2009, Proceedings of the National Academy of Sciences.
[14] E. Seto,et al. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men , 2008, Nature Reviews Molecular Cell Biology.
[15] H. Lehr,et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice , 2008, Gut.
[16] Jay L. Morris,et al. Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. , 2013, Anticancer research.
[17] S. Hiebert,et al. Liver‐specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks , 2008, The EMBO journal.
[18] N. Sundaresan,et al. SIRT3 Is a Stress-Responsive Deacetylase in Cardiomyocytes That Protects Cells from Stress-Mediated Cell Death by Deacetylation of Ku70 , 2008, Molecular and Cellular Biology.
[19] Delin Chen,et al. Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.
[20] H. Nagase,et al. Epigenetics: differential DNA methylation in mammalian somatic tissues , 2008, The FEBS journal.
[21] M. Walther,et al. The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. , 2013, Leukemia research.
[22] Jessica E. Bolden,et al. Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.
[23] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Kristiansen,et al. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer , 2014, BMC Clinical Pathology.
[25] Zhenhao Hua,et al. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. , 2010, Urologic oncology.
[26] E. Sausville,et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Izumi Horikawa,et al. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. , 2005, Molecular biology of the cell.
[28] Carsten Denkert,et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression , 2013, BMC Cancer.
[29] Eric Verdin,et al. Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation , 2001, Science.
[30] G. Feldmann,et al. The NAD+-dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca2+ Responses* , 2012, The Journal of Biological Chemistry.
[31] C. Jacobs,et al. The epigenetic mechanism of mechanically induced osteogenic differentiation. , 2010, Journal of biomechanics.
[32] Ming-Shiang Wu,et al. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma , 2010, Autophagy.
[33] Limei Liu,et al. Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. , 2013, Cancer letters.
[34] J. Cheong,et al. Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells. , 2009, BMB reports.
[35] C. Busch,et al. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. , 2013, The Journal of nutritional biochemistry.
[36] R. Place,et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer , 2009, Oncogene.
[37] W. Weichert,et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy , 2008, British Journal of Cancer.
[38] W. Liao,et al. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors , 2013, BMC Cancer.
[39] S. Wang,et al. SIRT1 interacts with p73 and suppresses p73‐dependent transcriptional activity , 2007, Journal of cellular physiology.
[40] Cheng-Ping Yu,et al. SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin , 2012, Pathology & Oncology Research.
[41] Andrew J. Wilson,et al. HDAC4 promotes growth of colon cancer cells via repression of p21. , 2008, Molecular biology of the cell.
[42] R. Behringer,et al. Regulation of NF-κB Circuitry by a Component of the Nucleosome Remodeling and Deacetylase Complex Controls Inflammatory Response Homeostasis* , 2010, The Journal of Biological Chemistry.
[43] O. Witt,et al. HDAC11 is a novel drug target in carcinomas , 2013, International journal of cancer.
[44] A. Wróbel,et al. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. , 2014, Toxicology letters.
[45] F. Dequiedt,et al. Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.
[46] Xue-Ru Wu,et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo , 2007, Journal of Translational Medicine.
[47] W. Weichert,et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. , 2008, Neoplasia.
[48] S. Zhuang,et al. HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome‐dependent pathway , 2011, Journal of cellular biochemistry.
[49] Minoru Yoshida,et al. [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[50] R. Johnstone,et al. Histone deacetylase inhibitors in cancer therapy , 2007, Expert opinion on investigational drugs.
[51] Le Wang,et al. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer , 2011, Journal of hematology & oncology.
[52] Brigitte Schlegelberger,et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. , 2012, Gastroenterology.
[53] Andrew J. Wilson,et al. Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.
[54] Sung-Dae Cho,et al. A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells. , 2013, Molecular medicine reports.
[55] W. Gerald,et al. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. , 2009, American journal of translational research.
[56] G. Packham,et al. The NF-κB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes , 2010, Journal of hepatology.
[57] M. Duvic,et al. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma , 2007, Expert opinion on investigational drugs.
[58] G. Bartsch,et al. HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions , 2013, Experimental biology and medicine.
[59] A. Lutz,et al. Rapid changes in histone deacetylases and inflammatory gene expression in expert meditators , 2014, Psychoneuroendocrinology.
[60] Gordon B Mills,et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.
[61] H. Sitter,et al. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC , 2011, Virchows Archiv.
[62] V. Steele,et al. Chemopreventive Effects of an HDAC2-Selective Inhibitor on Rat Colon Carcinogenesis and APCmin/+ Mouse Intestinal Tumorigenesis , 2014, The Journal of Pharmacology and Experimental Therapeutics.
[63] Ronald Breslow,et al. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug , 2007, Nature Biotechnology.
[64] Guo-Zhong Ji,et al. Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. , 2013, International journal of molecular medicine.
[65] K. Nave,et al. HDAC-mediated Deacetylation of NF-κB is Critical for Schwann cell Myelination , 2011, Nature Neuroscience.
[66] Z. Herceg,et al. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. , 2008, Mutation research.
[67] J. Turnay,et al. Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells. , 2012, Biochimica et biophysica acta.
[68] W. Ellmeier,et al. Conditional Deletion of Histone Deacetylase 1 in T Cells Leads to Enhanced Airway Inflammation and Increased Th2 Cytokine Production , 2010, The Journal of Immunology.
[69] W. Grizzle,et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. , 2011, International journal of oncology.
[70] Delong Liu,et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents , 2010, Journal of hematology & oncology.
[71] L. Altucci,et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. , 2013, Blood.
[72] G. Kristiansen,et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma , 2010, Expert opinion on therapeutic targets.
[73] Alberto Mantovani,et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.
[74] E. Olson,et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. , 2008, The Journal of clinical investigation.